/MXCT

MaxCyte Inc

MXCT

$1.16USD↓-2.52%-0.03 today

MARKET CAP

119.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1

$2

AI Summary

Stalk

TrimMedium

MXCT remains in Stage 4 – Decline after the mid-July support breakdown confirmed sustained bearish control. Price trades below the 9/21/50 EMAs and the declining 200 DMA on elevated down-volume, and the Support Failure pattern suggests accelerating downside with the broken support acting as resistance. The asset is extremely oversold, so execution for the bearish medium-term thesis is best deferred. We will trim into strength, targeting rallies into the broken support zone and moving averages for entry.

↑Multi-platform Genentech license enhances recurring revenue streams
↑YoY net loss improvement from $12.4M to $8.9M reflects cost discipline
↓Q2 core revenue fell 15% to $6.5M; gross margin slipped to 77% from 82%

Full analysis →

Buying

7

institutions

Selling

3

institutions

New Positions

3

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	SELL	3.06 M	3.76 M	+-5.74 M	-39.1%	0.00%
CC Cadian Capital Management, LP Q2 2026	BUY	2.20 M	2.71 M	+478.22 K	+123.7%	0.20%
RT Renaissance Technologies LLC Q2 2026	SELL	1.91 M	2.35 M	+-82.40 K	+67.8%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	1.88 M	2.32 M	+661.59 K	+169.9%	0.00%
MM Millennium Management LLC Q2 2026	BUY	1.20 M	1.48 M	+1.16 M	+4799.5%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	955.72 K	1.18 M	+622.63 K	+402.4%	0.00%
MG Man Group Plc Q2 2026	BUYNEW	448.96 K	552.22 K	+448.96 K	+0.0%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUYNEW	299.85 K	368.82 K	+299.85 K	+0.0%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	BUYNEW	13.55 K	16.66 K	+13.55 K	+0.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	1.57 K	1.95 K	+-39.52 K	-93.0%	0.00%